Splicing mutations, mainly IVS6-1(G>T), account for 70% of fumarylacetoacetate hydrolase (FAH) gene alterations, including 7 novel mutations, in a survey of 29 tyrosinemia type I patients: SPLICING MUTATIONS OF FAH
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Hereditary tyrosinemia type I (HTI) is an autosomal recessive disease characterized by a deficiency in fumarylacetoacetate hydrolase (FAH) activity. In this work, the FAH genotype was established in a group of 29 HTI patients, most of them from the Mediterranean area. We identified seven novel mutations-IVS8-1(G>A, IVS10-2(A>T), 938delC, E6/I6del26, W78X, Q328X, and G343W-and two previously described mutations-IVS6-1(G>T) and IVS12+5(G>A). Fully 92.8% of the patients were carriers of at least one splice site mutation, with IVS6-1(G>T) accounting for 58.9% of the total number of alleles. The splice mutation group of patients showed heterogeneous phenotypic patterns ranging from acute forms with severe liver malfunction to chronic forms with renal manifestations and slow progressive hepatic alterations. Qualitative FAH cDNA expression was the same in all IVS6-1(G>T) homozygous patients regardless of their clinical picture. One patient with a heterozygous combination of a nonsense (Q328X) and a frameshift (938delC) mutation showed an atypical clinical picture of hypotonia and repeated infections. Despite the high prevalence of IVS12+5(G>A) in the northwestern European population, we found only two patients with this mutation in our group.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Overturf, K., Al-Dhalimy, M., Tanguay, R., Brantly, M., Ou, C.-N., Finegold, M., & Grompe, M. (1996) · Nature Genetics · doi:10.1038/ng0396-266 · Cited by 549
On the enzymic defects in hereditary tyrosinemia.
Lindblad, B., Lindstedt, S., & Steen, G. (1977) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.74.10.4641 · Cited by 447 · cited 2×
“Hereditary tyrosinemia type I (HT1 or HTI, MIM# 276700) is an autosomal recessive disease characterized by a deficiency in fumarylacetoacetate hydrolase (FAH; E.C. 3.7.1.2) activity, catalyzing the last step in the tyrosine catabolic pathway [Lindblad et al., 1977].”
BackgroundInfluentialTyrosinaemia type I and NTBC (2‐(2‐nitro‐4‐trifluoromethylbenzoyl)‐1,3‐cyclohexanedione)
Holme, E., & Lindstedt, S. (1998) · Journal of Inherited Metabolic Disease · doi:10.1023/a:1005410820201 · Cited by 264
Self-induced correction of the genetic defect in tyrosinemia type I.
Kvittingen, E. A., Rootwelt, H., Berger, R., & Brandtzaeg, P. (1994) · Journal of Clinical Investigation · doi:10.1172/jci117509 · Cited by 168
Grompe, M., St.-Louis, M., Demers, S. I., Al-Dhalimy, M., Leclerc, B., & Tanguay, R. M. (1994) · New England Journal of Medicine · doi:10.1056/nejm199408113310603 · Cited by 135 · cited 3×
“This figure may be higher in specific regions as a consequence of endogamic habits (carrier frequencies up to 1:20) or in isolated populations with a strong founder effect (e.g., the Sanguenay-Lac-St-Jean region in Quebec) [Grompe et al., 1994].”
BackgroundHereditary tyrosinemia type I: Self-induced correction of the fumarylacetoacetase defect
Kvittingen, E. A., Rootwelt, H., Brandtzaeg, P., Bergan, A., & Berger, R. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116393 · Cited by 102
van Amstel, J. K. P., Bergman, A. J. I. W., van Beurden, E. A. C. M., Roijers, J. F. M., Peelen, T., van den Berg, I. E. T., Poll-The, B. T., Kvittingen, E. A., & Berger, R. (1996) · Human Genetics · doi:10.1007/bf00218833 · Cited by 60
Cited by
Demers, S. I., Russo, P., Lettre, F., & Tanguay, R. M. (2003) · Human Pathology · doi:10.1016/s0046-8177(03)00406-4 · Cited by 67
Tyrosinemia type 1 in Spain: Mutational analysis, treatment and long‐term outcome
Couce, M. L., Dalmau, J., del Toro, M., Pintos‐Morell, G., Aldámiz‐Echevarría, L., & Spanish Working Group on Tyrosinemia type1 (2011) · Pediatrics International · doi:10.1111/j.1442-200x.2011.03427.x · Cited by 46
Mutation Spectrum of Fumarylacetoacetase Gene and Clinical Aspects of Tyrosinemia Type I Disease
Dursun, A., Özgül, R. K., Sivri, S., Tokatlı, A., Güzel, A., Mesci, L., Kılıç, M., Aliefendioglu, D., Özçay, F., Gündüz, M., et al. (2011) · JIMD Reports · doi:10.1007/8904_2011_10 · Cited by 20
Epov, L., Srugo, I., Kassis, I., Bar‐Joseph, G., Mandel, H., & Kugelman, A. (2010) · Acta Paediatrica · doi:10.1111/j.1651-2227.2010.01901.x · Cited by 4
Metadata
- Authors
- Arranz, J. A., Piñol, F., Kozak, L., Pérez-Cerdá, C., Cormand, B., Ugarte, M., & Riudor, E.
- Venue
- Human Mutation
- Publisher
- Hindawi Limited
- Published
- 2002-08-21
- Volume
- 20
- Issue
- 3
- Pages
- 180-188
- ISSN
- 1059-7794 (ISSN-L)
- OpenAlex
- W2122394061
- Cited by
- 39
- References
- 7
- FWCI
- 1.22
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Splicing mutations, mainly IVS6-1(G>T), account for 70% of fumarylacetoacetate hydrolase (FAH) gene alterations, including 7 novel mutations, in a survey of 29 tyrosinemia type I patients: SPLICING MUTATIONS OF FAH. https://app.cochat.ai/papers/10.1002/humu.10084
- The paper
- Arranz, J. A., Piñol, F., Kozak, L., Pérez-Cerdá, C., Cormand, B., Ugarte, M., & Riudor, E. (2002). Splicing mutations, mainly IVS6-1(G>T), account for 70% of fumarylacetoacetate hydrolase (FAH) gene alterations, including 7 novel mutations, in a survey of 29 tyrosinemia type I patients: SPLICING MUTATIONS OF FAH. Human Mutation. https://doi.org/10.1002/humu.10084
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.